The comprehensive guide above covers 10 clinical scenarios based on the latest guidelines and authoritative textbooks. Here is a brief orientation to what's covered:
-
Chronic Stable HFrEF - The "Fantastic Four" GDMT pillars with precise start and target doses (ACEi/ARB → ARNI, beta-blocker, MRA, SGLT2i), plus diuretics for symptoms
-
HFrEF in African Americans - Hydralazine + isosorbide dinitrate (A-HeFT trial; 43% mortality reduction on top of GDMT)
-
Persistent Symptoms, HR ≥ 70 bpm (Sinus Rhythm) - Ivabradine 5→7.5 mg BID (SHIFT trial)
-
Refractory HFrEF (NYHA III-IV) - Vericiguat 2.5→10 mg OD (VICTORIA trial)
-
Residual Symptoms on Full GDMT - Digoxin at low dose (target 0.5-0.9 ng/mL, NOT > 1.2 ng/mL)
-
Acute Decompensated HF (ADHF) - Phenotype-based: IV furosemide, nitrates, inotropes (dobutamine), vasopressors (norepinephrine preferred in cardiogenic shock - SOAP II trial)
-
HFpEF (EF ≥ 50%) - SGLT2 inhibitors (EMPEROR-Preserved, DELIVER) as best evidence; spironolactone for symptom/hospitalization reduction; beta-blockers do NOT help in sinus rhythm HFpEF
-
HF with CKD - Dose adjustments; finerenone (non-steroidal MRA) for HF+CKD+T2DM; SGLT2i down to eGFR ≥ 20
-
Post-MI Systolic Dysfunction - Early ACEi + carvedilol + eplerenone (EPHESUS)
-
HF with Atrial Fibrillation - Rate control strategy + anticoagulation